Forschungs- & Entwicklungsinformationsdienst der Gemeinschaft - CORDIS

FP5

RECOMBINANT BCG Berichtzusammenfassung

Project ID: ICA4-CT-2000-30032
Gefördert unter: FP5-INCO 2
Land: Brazil

immunogenicity and protective efficacy of rBCG-anaplasma antigen strains

Humoral and cellular immune responses of mice inoculated with recombinant Mycobacterium bovis BCG expressing the MSP1a antigen of Anaplasma marginale were evaluated. The msp1a gene was amplified by PCR and cloned into the mycobacterial expression vectors pUS2000 and pMIP12. Immunization of isogenic BALB/c mice with the rBCG/pUS2000-msp1a construct induced significant seroconversion to MSP1a (p<0,001), which was 26 times above pre-immunization levels at day 63 post initial immunization and which remained stable for the duration of the experiment (6 months). In contrast, rBCG/pMIP12-msp1a induced seroconversion at a level of 6 times above pre-immunization values, which peaked at day 63. Western blot analysis showed that sera derived from mice vaccinated with either rBCG construct recognized both native and recombinant forms of A. marginale MSP1a. In contrast to the humoral response data, immunization with rBCG/pMIP12-msp1a was found to induce a markedly stronger cellular response than that recorded for BCG/pUS2000-msp1a. These results clearly demonstrated the immunogenicity of rBCG expressing the MSP1a antigen and suggested that the immune responses were influenced by the level of antigen expression. Recombinant BCG expressing MSP1a constitutes a potential strategy of immunization against bovine anaplasmosis.

Kontakt

Odir DELLAGOSTIN, (Head of Biotechnology Centre)
Tel.: +55-53-32757350
Fax: +55-53-32757551
E-Mail-Adresse
Folgen Sie uns auf: RSS Facebook Twitter YouTube Verwaltet vom Amt für Veröffentlichungen der EU Nach oben